HIV protease inhibitory bis-benzamide cyclic ureas: A quantitative structure-activity relationship analysis

Journal of Medicinal Chemistry

Volumn 39, Issue 21, 1996, Pages 4299-4312

  Wilkerson, Wendell W ^a,b   Akamike, Emeka ^a   Cheatham, Walter W ^a   Hollis, Andrea Y ^a   Collins, R Dale ^a   DeLucca, Indawati ^a   Lam, Patrick Y S ^a   Ru, Yu ^a  

^a DUPONT COMPANY   (United States)

^b Dextron Corporation   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BENZAMIDE DERIVATIVE; PROTEINASE INHIBITOR; UREA DERIVATIVE;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; AMINO ACID SUBSTITUTION; ANTIVIRAL ACTIVITY; ARTICLE; DRUG SYNTHESIS; ENZYME INHIBITION; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYDROGEN BOND; NONHUMAN; PROTEINASE INHIBITION; STRUCTURE ACTIVITY RELATION; TARGET CELL; VIRUS INHIBITION; VIRUS REPLICATION;

ANTI-HIV AGENTS; BENZAMIDES; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; HIV PROTEASE INHIBITORS; HIV-1; KINETICS; RNA, VIRAL; STRUCTURE-ACTIVITY RELATIONSHIP; UREA; VIRUS REPLICATION;

EID: 0029797080     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm9602773     Document Type: Article

References (29)

1. Ueno, T.; Mitsuya, H. Current Status of the Development of HIV Protease Inhibitors and Their Clinical Potential. Clin, Immunother. 1995, 4, 451-461.
2. Wilkerson, W. W.; Hollis, A. Y.; Cheatham, W. W.; Lam, G. N.; Erickson-Viitanen, S.; Bacheler, L.; Cordova, B. C.; Klabe, R. M.; Meek, J. L. A Bis-[N-3-(1-Hydroxy-1-methyl-ethyl)-benzyl]-Cyclic Urea As A HIV Protease Inhibitor. BioMed. Chem. Lett. 1995, 5, 3027-3032.
3. Lam, P. Y.; Eyermann, C. J.; Hodge, C. N.; Jadhav, P. K.; DeLucca, G. V. New Cyclic Urea and Derivatives for Pharmaceutical Compositions Used as Retroviral Protease Inhibitors, used to Treat HIV and Viral Infections. WO 9307128-A1, 1993.
4. Lam, P. Y. S.; Jadhav, P. K.; Eyermann, C. J.; Hodge, C. N.; Ru, Y.; Bacheler, L. T.; Meek, J. L.; Otto, M. J.; Rayner, M. M.; Wong, Y. N.; Chang, C.-H.; Weber, P. C.; Jackson, D. A.; Sharp, T. R.; Erickson-Viitanen, S. Rational Design of Potent, Bioavailable, Non-peptide Cyclic Ureas as HIV Protease Inhibitors. Science 1994, 263, 380-284.
5. Noller, C. M. In Organic Synthesis Collective Volume; Blatt, A. H., Ed.; John Wiley & Sons: New York, 1943; Collect. Vol. II, p 586.
6. Coste, J.; Campagne, J.-M. A Propos de l'Estérification des Acides Carboxyliques par le BOP ou le PyBOP. (Esterification of carboxylic acids by BOP or PyBOP.) Tetrahedron Lett. 1995, 36, 4253-4256.
7. Basha, A.; Lipton, M.; Weinreb, S. M. A Mild, General Method for Conversion of Esters to Amides. Tetrahedron Lett. 1977, 4171-4174.
8. Cheng, Y.-S. E.; Yin, F. H.; Foundling, S.; Blomstrom, D.; Kettner, C. A. Stability and Activity of Human Immunodeficiency Virus Protease: Comparison of the Natural Dimer with a Homologous, Single-chain Tethered Dimer. Proc. Natl. Acad. Sci. U.S.A. 1990, 87, 9660-9664.
9. Erickson-Viitanen, S.; Manfredi, J.; Viitanen, P.; Tribe, D. E.; Tritch, R.; Hutchison, C. A., III; Loeb, D. D.; Swanstrom, R. Cleavage of HIV-1 gag Polyprotein Synthesized In Vitro: Sequential Cleavage by Viral Protease. AIDS Res. Hum. Retroviruses 1989, 5, 577-591.
10. Bacheler, L.; Paul, M.; Otto, M. J.; Jadhav, P. K.; Stone, B. A.; Miller, J. A. An Assay for HIV RNA in Infected Cell Lysates, and Its Use for the Rapid Evaluation of Antiviral Efficacy. Antiviral Chem. Chemother. 1994, 5, 111-121.
11. Steward, J. J. P. MOPAC: A Semiemperical Molecular Orbital Program. J. Comput.-Aided Mol. Des. 1990, 4, 1-105.
12. Waller, C. L.; Oprea, T. I.; Giolitti, A.; Marshall, G. R. Three-Dimensional QSAR of Human Immunodeficiency Virus (I) Protease Inhibitors. 1. A CoMFA Study Employing Experimentally-Determined Alignment Rules. J. Med. Chem. 1993, 36, 4152-4160.
13. Oprea, T. I.; Waller, C. L.; Marshall, G. R. Three-Dimensional Quantitative Structure-Activity Relationship of Human Immunodeficiency Virus (I) Protease Inhibitors. 2. Predictive Power Using Limited Exploration of Alternate Binding Modes. J. Med. Chem. 1994, 37, 2206-2215.
14. Swain, C. G.; Lupton, E. C., Jr. Field and Resonance Components of Substituent Effects. J. Am. Chem. Soc. 1968, 90, 4328-4337.
15. Martin, Y. C. Quantitative Drug Design. A Critical Introduction; Marcel Dekker, Inc.: New York, 1978; Vol. 8, pp 95-97.
16. Hansch, C.; Leo, A.; Hoekman, D. Exploring QSAR. Hydrophobic, Electronic, Steric Constants; American Chemical Society: Washington, DC, 1995.
17. Hansch, C.; Leo, A. Substituent Constants for Correlation Analysis in Chemistry and Biology; John Wiley and Sons: New York, 1979.
18. Hansch, C.; Leo, A.; Unger, S. H.; Kim, K. H.; Nikaitani, D.; Lien, E. J. "Aromatic" Substituent Constants for Structure-Activity Correlations. J. Med. Chem. 1973, 16, 1207-1216.
19. Topliss, J. G.; Costello, R. J. Chance Correlations in Structure-Activity Studies Using Multiple Regression Analysis. J. Med. Chem. 1972, 15, 1066-1068.
20. Topliss, J. G.; Edwards, R. P. Chance Factors in Studies of Quantitative Structure-Activity Relationships. J. Med. Chem. 1979, 22, 1238-1244.
21. Hansch, C.; Leo, A. Exploring QSAR. Fundamentals and Applications in Chemistry and Biology; American Chemical Society: Washington, DC, 1995.
22. Kim, K. H. In 3D QSAR in Drug Design; Kubinyi, H., Ed.; ESCOM: Leiden, 1993; pp 619-642.
23. Franke, R. Theoretical Drug Design Methods; Elsevier: Amsterdam, 1984; Vol. 7, pp 313-363.
24. Test-1- test-8 were synthesized contemporaneously with this study and not used to generate the regression models. They were used to test the predictability of eqs 3 and 4. Test-1 and -2 are characterized in the Experimental Section. Test-3-test-8 are the subject of another publication (manuscript in preparation) by P. K. Jadhav of these laboratories.
25. Livington, D. J.; Pazhanisamy, S,; Porter, D. J.; Partaledis, J A.; Tung, R. D.; Painter, G. R. Weak Binding of VX-478 to Human Plasma Proteins and Implications for Anti-Human Immunodeficiency Virus Therapy. J. Infect. Dis. 1995, 172, 238-245.
26. Kempf, D. J.; Marsh, K. C.; Denissen, J.; McDonald, E.; Vasavanonda, S.; Flentge, C.; Green, B. G.; Fino, L.; Park, C.; Kong, X.; Wideburg, N. E.; Saldiva, A.; Ruiz, L.; Kati, W. M.; Sham, H. L.; Robins, T.; Stewart, K. D.; Plattner, J. J.; Leonard, J.; Norbeck, D. ABT-538 is a Potent Inhibitor of Human Immunodeficiency Virus Protease with High Oral Bioavailability in Humans. Proc. Natl. Acad. Sci. U.S.A. 1995, 92, 2484-2488.
27. Galpin, S.; Roberts, N. A.; O'Connor, T.; Jeffereies, D. J.; Kinchington, D. Antiviral Properties of the HIV-1 Protease Inhibitor Ro 31-8959. Antiviral Chem. Chemother. 1994, 5, 43-45.
28. Vacca, J, P.; Dorsey, B. D.; Schleif, W. A.; Levin, R. B.; McDaniel, S. L.; Darke, P. L.; Zugay, U. J.; Quintero, J. C.; Blahy, O. M.; Roth, E.; Sardana, V. V.; Schlabach, A. J.; Graham, P. I.; Condra, J. H.; Gotlieb, L.; Holloway, M. K.; Lin, J.; Chen, I.-W.; Vastag, K.; Ostovic, D.; Anderson, P. S.; Emini, E. A.; Huff, J. R. L-735,-524: An Orally Bioavailable Human Immunodeficiency Virus Type 1 Protease Inhibitor. Proc. Natl. Acad. Sci. U.S.A. 1994, 91, 4096-4100.
29. De Clercq, E. Toward Improved Anti-HIV Chemotherapy: Therapeutic Strategies for Intervention with HIV Infections. J. Med. Chem. 1995, 38, 2491-2517.